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Introduction: The NLRP3 inflammasome produces interleukin (IL)-1b and IL-18, which
when chronically activated by transforming growth factor (TGF)-b1, contribute to fibrosis.
The recombinant form of the anti-fibrotic hormone, relaxin (RLX), suppresses the pro-
fibrotic influence of TGF-b1 and toll-like receptor (TLR)-4 on NLRP3 inflammasome
priming and activity in human cardiac myofibroblasts and mice with cardiomyopathy.
However, whether RLX also modulates components of the myofibroblast NLRP3
inflammasome remains unknown.
Methods and Results: Stimulation of a human dermal fibroblast (HDF) cell line with TGF-
b1 [5 ng/ml; to promote myofibroblast (HDMF) differentiation], LPS (100 ng/ml; to prime
the NLRP3 inflammasome) and ATP (5 mM; to activate the NLPR3 inflammasome) (T+L
+A) significantly increased NLRP3 inflammasome priming and activity after 8 and 72 h;
and a-SMA expression (myofibroblast differentiation) and collagen-I deposition after 72 h.
siRNA-induced knock-down of NLRP3 inflammasome priming components (NLRP3,
ASC, caspase-1) in T+L+A-stimulated HDMFs for 24 h, completely knocked-down
each component after 72 h. RLX (100 ng/ml) administration to T+L+A-stimulated
HDMFs after control, NLRP3 or ASC siRNA transfection, equivalently suppressed IL-
1b, pro-IL-18, a-SMA, and collagen-I protein levels (by 40%–50%; all p<0.05 vs. T+L+A)
after 72 h, as determined by Western blotting. These RLX-induced effects were abrogated
by siRNA knock-down of caspase-1.
Conclusion: The anti-fibrotic actions of RLX appear to require modulation of caspase-1
within the myofibroblast NLRP3 inflammasome.
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Inflammation is initiated by the innate immune system as
part of a natural wound healing response to tissue injury.
The infiltration of activated innate immune cells (Wynn, 2008)
and their ability to secrete pro-inflammatory and pro-
fibrotic cytokines and growth factors such as transforming
growth factor (TGF)-b1 and several interleukins (ILs)
including IL-1b and IL-18 are initiated to facilitate wound
healing. However, when these factors are over-activated, they
eventually contribute to fibrosis (Kolb et al., 2001; Gasse et al.,
2007). These pro-fibrotic cytokines stimulate extracellular
matrix (ECM)-producing fibroblasts to proliferate and
differentiate into activated myofibroblasts (Wynn, 2008).
These chronically activated myofibroblasts interact with the ECM
and deposit large amounts of ECM proteins, predominantly
collagens, to facilitate wound healing. However, the over-
production of ECM deposition contributes to anomalous tissue
remodeling and scarring that displaces the integrity of the healthy
tissue (Wynn and Ramalingam, 2012; Schroer and Merryman,
2015; Li et al., 2018; Frangogiannis, 2019; Humeres and
Frangogiannis, 2019).
The nucleotide-binding oligomerization domain, leucine-
rich repeat and pyrin domain-containing protein 3 (NLRP3)
inflammasome is a large multiprotein complex (Mangan et al.,
2018; Zhou et al., 2018) that is expressed by several cell
types including macrophages (Rodriguez-Alcazar et al.,
2019), epithelial cells, microvascular endothelial cells and
myofibroblasts (Boza et al., 2016). The NLRP3 inflammasome
is formed to mediate the wound healing response to tissue
injury via the production of IL-1b and IL-18. However, when
chronically activated, it has emerged as a key contributor to
fibrosis progression (Kolb et al. , 2001). The NLRP3
inflammasome consists of the sensor molecule NLRP3, the
adaptor protein apoptosis-associated speck-like protein
containing a c-terminal caspase-recruitment domain (ASC),
and the effector protease, caspase-1. The maturation and release
of IL-1b is instigated via a two-step signaling process. The first
“priming signal” synthesizes pro-IL-1b and pro-IL-18 and
upregulates the expression of NLRP3 inflammasome
components including NLRP3, ASC and pro-caspase-1. The
second “activation signal” assembles the components of the
NLRP3 inflammasome into the tri-partite protein complex,
resulting in its activation, caspase-1 activation, and
subsequent maturation and secretion of IL-1b and IL-18.
TGF-b1 and toll-like receptor (TLR)-4 are known inducers of
the NLRP3 inflammasome in myofibroblasts (Boza et al., 2016),
while lipopolysaccharide (LPS) and adenosine triphosphate
(ATP) can be used experimentally to prime and activate the
inflammasome, respectively (Boza et al., 2016; Cáceres et al.,
2019). Currently, there is a lack of available therapies that
directly target scar tissue accumulation in damaged organs.
Accordingly, a better understanding of the molecular
mechanism involved in myofibroblast NLRP3 inflammasome-
induced fibrosis progression may lead to improved and effectiveFrontiers in Pharmacology | www.frontiersin.org 2therapeutic targeting of NLRP3 inflammasome activation to
treat fibrosis-induced end-organ damage and dysfunction.
The recombinant form of the peptide hormone relaxin,
serelaxin (RLX), has emerged as a rapidly-acting anti-fibrotic
therapy (Nistri et al., 2007; Du et al., 2010; Samuel et al., 2017),
signaling via its cognate G protein-coupled receptor, relaxin family
peptide receptor (RXFP)1 (Bathgate et al., 2013). Several lines of
evidence have indirectly suggested that RLX may also inhibit the
NLRP3 inflammasome to mediate its anti-fibrotic actions. First,
RLX can suppress the pro-fibrotic influence of known inducers of
myofibroblast NLPR3 inflammasome activity, including TGF-b1
(Unemori and Amento, 1990; Mookerjee et al., 2009; Sarwar et al.,
2015; Wang et al., 2016) and TLR-4 (Chen et al., 2017). RLX has
been found to inhibit TGF-b1 signal transduction at the level of
intracellular Smad2, either through direct effects on cyclic
guanosine monophosphate (cGMP) (Kocan et al., 2017) or by
signaling through a RXFP1-extracellular signal-regulated kinases
(ERK)-1/2 phosphorylation-neuronal nitric oxide (NO) synthase
(nNOS)-NO-soluble guanylyl cyclase (sGC)-cGMP-dependent
pathway (Mookerjee et al., 2009; Sarwar et al., 2015; Wang et al.,
2016). This in turn results in the suppression of TGF-b1-induced
myofibroblast differentiation and myofibroblast-induced collagen
production (the basis offibrosis). Second, RLX has also been found
to suppress both TGF-b1- and IL-1b-mediated collagen synthesis
and secretion in human dermal myofibroblasts (Unemori and
Amento, 1990). Third, RLX was shown to suppress the pro-
inflammatory and/or pro-fibrotic influence of IL-1b and IL-18
in vivo, in experimental models of renal ischemia/reperfusion
injury (Collino et al., 2013) and atrial fibrillation (Beiert et al.,
2017). Finally, RLX was found to attenuate myocardial ischemia/
reperfusion injury by inhibiting caspase-1 activity (Valle Raleigh
et al., 2017). However, caspase-1 activity can be modulated by
several inflammasomes and no direct evidence was shown to link
the findings obtained to the NLRP3 inflammasome in the latter
study (Valle Raleigh et al., 2017).
We recently demonstrated in TGF-b1-stimulated human
cardiac myofibroblasts in vitro and in the left ventricle of mice
subjected to isoproterenol-induced cardiomyopathy in vivo that
RLX could inhibit the TGF-b1/IL-1b/IL-18 axis via a RXFP1-
nNOS-TLR-4-NLRP3 inflammasome-dependent mechanism
(Cáceres et al., 2019). While these findings confirmed for the
first time that RLX could target inducers (TGF-b1 and TLR-4) of
the myofibroblast NLRP3 inflammasome to mediate its anti-
fibrotic actions, it was unclear whether RLX could also modulate
the NLPR3 inflammasome itself to inhibit myofibroblast
differentiation and collagen-I deposition. Hence, in this study,
we extended our recent findings to further delineate whether
RLX also modulated the myofibroblast NLRP3 inflammasome to
mediate its anti-fibrotic actions on myofibroblast differentiation
and collagen I deposition. This was addressed using a RXFP1-
expressing (Hossain et al., 2011; Chow et al., 2012) human
dermal fibroblast (HDF) cell line subjected to siRNA-induced
knock-down of specific components of NLRP3 inflammasome
priming, NLRP3, ASC, or caspase-1.August 2020 | Volume 11 | Article 1201
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Materials
The BJ3 human dermal fibroblast (HDF) cell line used in this
study was kindly provided by William C. Hahn (Department of
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA).
Recombinant human TGF-b1 was obtained from In Vitro
Technologies (#240-B, Minneapolis, MN, United States).
Recombinant human gene-2 (H2) relaxin was generously
provided by Corthera Inc (San Mateo, CA, United States; a
subsidiary of Novartis International AG, Basel, Switzerland). LPS
(#L2630) and ATP (#A6419) were both obtained from Sigma-
Aldrich (Vic, Australia).
Culture of HDFs
BJ3 HDFs were characterized as described before (Chow et al.,
2012) and cultured in DMEMmedium containing 17% medium-
199, 15% fetal bovine serum (FBS), 1% penicillin (50 U/ml)/
streptomycin (50 mg/ml), 1% L-glutamine (200 mM) and 2.2%
HEPES buffer (all obtained from Life Technologies, Mulgrave,
Vic, Australia). HDFs were cultured in T-175 cm2 flasks at 37°C,
passaged when 80%–90% confluent, and used between passages
10–14 for all of the outlined studies. At these passages, these cells
were shown to express RXFP1 (Chow et al., 2012).
Treatment of WT Human Dermal
Myofibroblasts (HDMFs)
Wild-type (WT) BJ3 HDFs were seeded at a density of 1-1.5x105
cells/well in 12-well plates and treated with TGF-b1 (T, 5 ng/ml)
to stimulate the differentiation of these cells into myofibroblasts
(HDMFs). Sub-groups of T-stimulated HDMFs were also treated
with the NLRP3 inflammasome primer, LPS (L, 100 ng/ml) and
activator, ATP (A, 5 mM) (T+L+A) to ensure activation of the
inflammasome on myofibroblasts. As a control, separate sub-
groups of cells were stimulated with L+A (without T), to
determine the effects of L+A stimulation on HDFs.
Sub-groups of T- or T+L+A-treated HDMFs were then either
left untreated or treated with RLX (RLX or R, 16.8 nM, which is
equivalent to 100 ng/ml) for 8 h [when NLRP3 inflammasome
activation is optimally measured (Boza et al., 2016)] or for 72 h
[when changes in TGF-b1-induced myofibroblast differentiation
and collagen I deposition could be measured (Samuel et al.,
2004)]. The doses of each factor used were previously reported in
studies that induced expression of the NLRP3 inflammasome
(Boza et al., 2016) and determined the therapeutic effects of RLX
on the myofibroblast NLRP3 inflammasome (Cáceres et al.,
2019). Measures of NLRP3 priming [NLRP3, ASC and (pro)-
caspase-1] and activity (IL-1b and IL-18) were detected after 8 h,
while changes in NLRP3 priming, myofibroblast differentiation
(a-SMA expression), and collagen I deposition (as measures of
fibrosis) were detected following 72 h in T-, T+R-, T+L+A-, and
T+L+A+R-treated HDMFs. These studies were conducted 6–8
separate times in duplicate.
HDMF siRNA Transfection Studies
BJ3 HDMFs were seeded at a density of 1–1.5x105 cells/well in
12-well plates, as described above. Short-interfering-RNAFrontiers in Pharmacology | www.frontiersin.org 3(siRNA) knock-down technology was used to downregulate the
expression of specific components of NLRP3 inflammasome
priming, compared to control siRNA, in transfected cells.
Lipofectamine RNAiMax transfection reagent (#13778030; Life
Technologies), Opti-MEM reduced serum medium (#11058021;
Life Technologies) and four separate individual siRNAs—one
control siRNA (#sc-37007), and three siRNAs each targeting
NLRP3 (#sc-45469), ASC (#37281), or caspase-1 (#29235) were
prepared separately (all purchased from Santa Cruz
Biotechnology, Dallas, TX, United States). Lipofectamine
RNAiMax was diluted 1:100 in Opti-MEM reduced serum
medium and left to incubate for 30 mins at room temperature
(RT). Each of the siRNAs were also individually diluted 1:100 in
Opti-MEM medium in separate tubes and left to incubate for
30min at RT. The Lipofectamine RNAiMax/Opti-MEM mixture
was then split into separate tubes and the siRNA/Opti-MEM
mixtures were added to the Lipofectamine RNAiMax/Opti-
MEM mixtures. These were incubated for an additional 30 min
prior to transfecting individual wells of HDFs to induce
lipofectamine-mediated siRNA-knock-down of NLRP3, ASC or
caspase-1 for 24 h. Separate wells of each plate were also treated
with the CTL siRNA for the same time-period. The following
day, the transfection medium was replaced with media and
HDFs were left to rest for an additional day. The following
day, transfected HDFs were treated in duplicate, as detailed
below. In one set of experiments, HDFs were transfected with
the CTL siRNA for 24 h before sub-groups of cells were further
treated with T+L+A or T+L+A+R for 72 h. This was conducted
to confirm that the effects RLX on measures of NLRP3 priming
[NLRP3, ASC, and (pro)-caspase-1] and activity (IL-1b and IL-
18) as well as fibrosis (a-SMA and collagen I) in cells transfected
with the CTL siRNA reflected that observed following
corresponding treatment of untransfected WT HDMFs. These
studies were conducted 4–6 separate times in duplicate. In a
separate set of experiments, HDFs separately transfected with the
control or individual siRNAs that targeted NLRP3, ASC, or
caspase-1, were treated with T or T+L+A for 8 h or 72 h, to
confirm knock-down of the individual NLRP3 inflammasome
components. The siRNA-induced knock-down efficiency of each
siRNA was determined by measuring the protein expression
levels of NLRP3, ASC and (pro)-caspase-1, respectively. These
studies were conducted 4–6 separate times in duplicate. In a final
set of experiments, HDFs individually transfected with NLRP3
siRNA, ASC siRNA, caspase-1 siRNA or control siRNA for 24 h,
were then treated with T+L+A or T+L+A+R for 72 h to
determine which component(s) of the myofibroblast NLRP3
inflammasome RLX required an interaction with to mediate its
inhibitory effects on myofibroblast differentiation and collagen I
deposition. These studies were conducted 4–6 separate times
in duplicate.
Immunocytochemistry
BJ3 HDFs (1-1.5x106/well) were plated and grown on poly-D-
lysine-coated coverslips in 12-well plates for 24 h. BJ3 HDFs were
then treated with T+L+A in the absence or presence of RLX for
8 h (to study the extent of NLRP3 colocalisation with caspase-1),
and separately, for 72 h (to induce expression of a-SMA, as aAugust 2020 | Volume 11 | Article 1201
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treatment, in each case, BJ3 HDMFs were washed once with
warmed PBS, fixed for 10min in 4% PFA, and washed once again
in warmed PBS, prior to staining. Treated BJ3 HDMFs were then
blocked with 10% normal goat serum containing 0.2% triton X-
100 for 30 min, and then incubated overnight in either goat
polyclonal anti-NLRP3 (ab4207; 1:500 dilution; Abcam, Vic,
Australia), rabbit polyclonal anti-caspase-1 (ab1872; 1:750
dilution; Abcam, Vic, Australia), or rabbit polyclonal anti-a-
SMA (ab5694; 1:500 dilution; Abcam, Vic, Australia) primary
antibodies. The following day, primary antibodies were then
aspirated and treated BJ3 HDMFs were washed 3 times in
warmed PBS prior to incubation in the appropriate Alexa
Fluor 488 or 594 secondary antibody (Alexa Fluor 488 donkey
anti-goat IgG; #A11012; 1:1000 dilution; or Alexa Fluor 594 goat
anti-rabbit IgG; #A20185; 1:750 dilution; both purchased from
Life Technologies, Vic, Australia). Antibody-stained BJ3 HDMFs
were then washed 3 times in warmed PBS, and cells mounted
with a drop of VECTASHIELD HardSet™ Mounting Medium
containing DAPI to preserve fluorescence (Vector Laboratories;
Meadowbrook, Qld, Australia) on each coverslip, following
mounting of another coverslip and left to dry. T+L+A-treated
BJ3 HDMFs dual stained for NLRP3 and caspase-1 were assessed
for the degree of NLRP3 and caspase-1 co-localisation compared
to T+L+A+R-treated BJ3 HDMFs in a-SMA differentiated
HDMFs. All stained slides were scanned by Monash Micro
Imaging using a Leica DMi8 Dexter microscope, at 40x
magnification. Five to six field of view were randomly captured
and analyzed using ImageJ Software (ImageJ, United States) to
examine differences in the extent of NLRP3 and caspase-1 co-
localization in T+L+A- vs. T+L+A+R-treated HDMFs.
Western Blotting
Following the various treatment groups examined in wild-type
HDMFs, as well as in cells transfected with the CTL or individual
siRNAs to NLRP3, ASC or caspase-1, the media was removed
and the cell layer from treatment groups were lifted and collected
via incubation in accutase solution (500 ml per well; Sigma-
Aldrich, Castle Hill, NSW, Australia) for 10 mins at 37°C.
Protein was extracted from the cell layer in 20 ml of 1x RIPA
lysis buffer, prepared from supplementing a 10x RIPA buffer
(#9806) with PMSF (#8553), phosphatase/protease inhibitor
(#5872) (all purchased from Cell Signalling, Danvers, MA,
United States), and double-distilled water. The suspension was
left to incubate in ice for 1 h, followed by centrifugation at 1500
rpm for 10 min at 4°C to pellet any cellular debris, leaving
protein in solution. The supernatant containing the protein was
then transferred to a separate Eppendorf tube, which was
subsequently stored at -20°C until required for use. Equivalent
volumes of protein from HDMF-cell layers were electrophoresed
on mini-protean 4%–15% precast gels and analyzed by Western
blotting using monoclonal antibodies to NLRP3 (#15101; 1:1000
dilution; Cell Signaling Technology, Danvers, MA, United
States), ASC (ab155970; 1:1000 dilution; Abcam, Cambridge,
MA, United States), pro-caspase-1 (#3866; 1:1000 dilution; Cell
Signaling Technology), pro-IL-1b (MAB601-100; 1:1000Frontiers in Pharmacology | www.frontiersin.org 4dilution; In Vitro Technologies, Noble Park North, Vic,
Australia), pro-IL-18 (D043-3; 1:1000 dilution; In Vitro
Technologies), and a-SMA (M0851; 1:1000 dilution; Dako/
Agilent Technologies, Mulgrave, Vic, Australia); or a
polyclonal antibody to collagen I (ab34710; 1:1000 dilution;
Abcam). The equivalent loading of protein between samples
was confirmed using a monoclonal antibody to the house-
keeping protein, GAPDH (ab8245; 1:1000 dilution; Abcam). In
each case, appropriate anti-mouse or anti-rabbit HRP conjugated
secondary antibodies (Cell Signaling Technologies) were used,
while blots were detected using the Clarity Western ECL
substrate detection kit and quantified by densitometry with a
ChemiDoc™ MP Imaging System and Image Lab version 6.0
software (both from Bio-Rad Laboratories, Richmond, CA,
United States). The density of each parameter was corrected
for GAPDH protein levels, and then expressed relative to the
indicated control group in each case, which was expressed as 1 in
each case.
Measurement of Caspase-1 and
IL-1b Activity
As caspase-1 and IL-1b activity are difficult to measure at the
cellular level (based on cell number) (Cáceres et al., 2019), BJ3
HDMFs were seeded at a density of 1–1.5x106 cells/well in 12-
well plates. HDMFs were then transfected with CTL or caspase-1
siRNA for 24 h. Transfected HDMFs were then treated either
with T+L+A or T+L+A+R for 8 h. After 8 h, the media from nine
sets of duplicate samples (18 ml) for each treatment group were
pooled and concentrated down to 300 µl (x60) using Amicon®
Ultra-4 centrifugal filter units with a 10 kDa cut-off (Merck
Millipore, Vic, Australia). Concentrated media samples were
then assayed in triplicate using a R&D Systems Human IL-1b/
IL-1F2 Quantikine ELISA and Human Caspase-1/ICE
Quantikine ELISA Kits (In Vitro Technologies, Vic, Australia),
according to manufacturer’s instructions.
Statistical Analysis
All statistical analysis was performed using GraphPad Prism v7.0
(GraphPad Software Inc., CA, United States). All data was
analysed via a one-way ANOVA with Neuman-Keuls post-hoc
test for multiple comparisons between groups. In each case,
results were expressed as the relative mean ± SEM with a p-
value <0.05 considered statistically significant.RESULTS
Effects of RLX on NLRP3 Inflammasome
Priming and Activation in Wild-Type
HDMFs After 8 h
Wild-type (WT) BJ3 HDFs were stimulated with LPS+ATP (L
+A) or with TGF-b1 (T) to promote their differentiation into
myofibroblasts (HDMFs) as well as T+L+A to promote the
induction of the NLRP3 inflammasome in T-stimulated
HDMFs for 8 h [the optimal time-point at which NLRP3August 2020 | Volume 11 | Article 1201
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et al., 2016)]. While L+A-stimulated HDFs did not undergo any
marked changes in NLRP3 inflammasome components (NLRP3,
ASC, pro-caspase-1; Supplementary Table 1); T+L+A-
stimulated HDMFs had significantly increased protein
expression of measures of NLRP3 inflammasome priming,
NLRP3, ASC and pro-caspase-1 (by 45–120%), as well as
activity, pro-IL-1b (by ~4-fold) and pro-IL (by ~28%) after
8 h, as determined by Western blotting (Figures 1A, B, all
p<0.05 vs. T alone). The T+L+A-stimulated increase in cellular
pro-caspase-1 and pro-IL-1b protein expression correlated with
a significant increase in maturely secreted caspase-1 and IL-1b
activity (Figure 1C, both p<0.01 vs. T alone), as determined by
ELISA analysis of concentrated media samples. RLX (R, 100 ng/
ml) administration to T alone-stimulated HDMFs did not
significantly affect any of these end-points measured. However,
RLX administration to T+L+A-stimulated HDMFs significantly
inhibited NLRP3, ASC, pro-caspase-1, and pro-IL-18 protein
expression as well as mature IL-1b activity to levels that were no
longer different to that measured in T alone-stimulated cells
(Figures 1B, C, all p<0.05 vs. T+L+A); and partially inhibited
pro-IL-1b protein expression (by ~63%) and mature caspase-1
levels (by ~36%) (Figures 1A, C, both p<0.05 vs. T+L+A; p<0.05
vs. T alone). RLX administration to T+L+A-stimulated WT
HDMFs also reduced the degree of co-localization between
NLRP3 and caspase-1 in these cells, compared to T+L+A-
stimulated cells alone (Figure 1D).
Effects of RLX on NLRP3 Inflammasome
Priming/Activation and Fibrosis in WT
HDMFs After 72 h
WT BJ3 HDFs were separately stimulated with L+A, T or T+L+A
for 72 h (representing the time point at which changes in
markers of fibrosis could be measured from myofibroblasts),
and T or T+L+A-stimulated HDMFs co-treated with RLX (R)
over the same time-period. Once again, L+A-stimulation of HDF
failed to induce any marked changes in NLRP3 inflammasome
components (NLRP3, ASC, pro-caspase-1; Supplementary
Table 1). On the other hand, T+L+A-stimulated HDMFs had
significantly increased protein expression of NLRP3, ASC, pro-
caspase-1 (by ~38-155%), pro-IL-1b (by ~3.5-fold), and pro-IL-
18 (by ~125%), which corresponded to a modest but significant
increase in a-SMA (by ~20%) and collagen I (by ~30%) protein
expression (Figure 2, all p<0.05 vs. T alone) after 72 h. RLX
significantly inhibited a-SMA and collagen I protein expression
in T alone-stimulated cells (Figure 2, by ~15-21%; both p<0.05
vs. T alone) in the absence of having any effects on measures of
the NLRP3 inflammasome. However, RLX fully inhibited the T
+L+A-stimulated increase in NLRP3, ASC and pro-caspase-1
(Figure 2, all p<0.05 vs. T+L+A); partially inhibited the T+L+A-
stimulated increase in pro-IL-1b (Figure 2, by ~70%; p<0.01 vs.
T+L+A; p<0.05 vs. T alone); and further inhibited the T+L+A-
stimulated increase in levels of a-SMA and collagen I protein
expression (Figure 2, both p<0.01 vs. T+L+A) to those that were
measured from RLX treatment of T alone-stimulated cells
(Figure 2).Frontiers in Pharmacology | www.frontiersin.org 5Validation of Lipofectamine-siRNA-
Mediated Knock-Down of NLRP3
Inflammasome Components in WT HDMFs
We first determined whether the control (CTL) siRNA obtained
had any effects on the NLRP3 inflammasome-inhibitory and
anti-fibrotic effects of RLX in HDMFs. Consistent with the data
obtained from RLX-treated WT HDMFs after 72 h (Figure 2),
RLX treatment of CTL siRNA transfected-HDMFs stimulated
with T+L+A (CTL siRNA+T+L+A+R), significantly inhibited
protein expression levels of NLRP3, ASC, pro-caspase-1, pro-IL-
1b, pro-IL-18, a-SMA and collagen I (Figures 3A, B, all p<0.05
vs. CTL siRNA+T+L+A); as well as mature levels of caspase-1
and IL-1b activity (Figure 3C, both p<0.05 vs. CTL siRNA+T+L
+A) after 72 h. These findings indicated that the anti-fibrotic
effects of RLX in T+L+A-stimulated HDMFs were not altered by
the presence of the CTL siRNA.
We then examined the siRNA-induced knock-down
efficiency of NLRP3, ASC or caspase-1 in T- and T+L+A-
stimulated HDMFs after 8 h and 72 h, in comparison to the
CTL siRNA, which should not have induced any knock-down of
the end-points measured (Figure 4). Compared to CTL siRNA
transfected-HDMFs that were stimulated with T alone, CTL
siRNA transfected-HDMFs stimulated with T+L+A expressed
significantly increased NLRP3, ASC, and pro-caspase-1 after 8 h
(by ˜50%–75%) and 72 h (by ˜40%–55%) (Figure 4, all p<0.05 vs.
CTL siRNA+T alone). siRNA-induced knock-down of NLRP3
(NLRP3 siRNA+T+L+A) or caspase-1 (caspase-1 siRNA+T+L
+A) did not reduce NLRP3 or caspase-1 expression, respectively
after 8 h, but induced complete knock-down of NLRP3 or
caspase-1 expression, respectively after 72 h (Figure 4, both
p<0.05 vs. CTL siRNA+T+L+A; no difference to CTL siRNA+T
alone). In contrast, siRNA-induced knock-down of ASC (ASC
siRNA+T+L+A) significantly reduced ASC expression from T+L
+A-stimulated HDMFs at 8 h and to a greater extent at 72 h
(Figure 4, both p<0.05 vs. CTL siRNA+T+L+A; difference to
CTL siRNA+T alone). These findings confirmed the complete
siRNA-induced knock-down of NLRP3, ASC, or caspase-1 from
T+L+A-stimulated HDMFs after 72 h.
The Effects of RLX on the Myofibroblast
NLRP3 Inflammasome in the Absence or
Presence of siRNA Treatment
Following establishment of siRNA-mediated knock-down of
NLRP3, ASC or caspase-1 in HDMFs, we next examined
whether RLX modulated the myofibroblast NLRP3
inflammasome to mediate its anti-fibrotic actions. The
stimulation of HDFs with T+L+A in the presence of CTL
siRNA (black bars), NLRP3 siRNA (blue bars), ASC siRNA
(purple bars), and caspase-1 siRNA (green bars), had comparable
effects on measures of NLRP3 priming and activity as well as
fibrosis (Figures 5A, B). In contrast, the administration of RLX
to CTL siRNA transfected and T+L+A-stimulated HDMFs
significantly downregulated measures of NLRP3 priming and
activity, and fibrosis (Figures 5A, B), which was consistent with
the effects of RLX shown in WT HDMFs (Figures 2A, B; in the
absence of siRNA). These inhibitory effects of RLX wereAugust 2020 | Volume 11 | Article 1201
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FIGURE 1 | The effects of RLX on NLRP3 inflammasome priming and activity in T- and T+L+A-stimulated WT BJ3 HDMFs after 8 h. (A) Representative Western
blots of NLRP3, ASC, pro-caspase-1, pro-IL-1b, and pro-IL-18 protein expression from HDMFs stimulated with TGF-b1 (T; 5 ng/ml), T+R (RLX; 100 ng/ml), T+L
(LPS; 100 ng/ml) +A (ATP; 5 mM), or T+L+A+R over 8 h. (B) Also shown are the mean ± SEM of each end-point measured from each treatment group studied,
corrected for GAPDH loading and expressed relative to the value in the T-treated group, which was expressed as 1 in each case; from n=6–8 separate experiments
conducted in duplicate. (C) Additionally shown are the mean ± SEM levels of mature, secreted active caspase-1 (pg/ml) and active IL-1b (pg/ml) activity detected
from the concentrated media of T-, T+L+A- and T+L+A+R-treated HDMFs after 8 h. *p<0.05, **p<0.01, ***p<0.001 vs. T-alone treated group; #p<0.05, ##p<0.01 vs.
T+L+A-treated group. (D) Representative images of NLRP3, caspase-1 and co-localization of NLRP3 and caspase-1 in T+L+A- vs. T+L+A+R-treated HDMFs
confirm the presence of the NLRP3 inflammasome in the HDMFs studied, and the ability of RLX to inhibit the individual and co-localized components of the
inflammasome. Scale bar; 100 mm.Frontiers in Pharmacology | www.frontiersin.org August 2020 | Volume 11 | Article 12016
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(Figures 5A, B). These findings suggested that RLX did not
modulate NLRP3 or ASC within the myofibroblast NLRP3
inflammasome to inhibit pro-IL-1b and pro-IL-18. However,
only in the presence of siRNA targeting caspase-1 (where
caspase-1 was knocked-down prior to stimulation with T+L+A
± R) was the ability of RLX to downregulate caspase-1 (but not
NLRP3 or ASC), pro-IL-1b, pro-IL-18, a-SMA, and collagen-I,
completely abrogated, indicating that RLX was able to modulateFrontiers in Pharmacology | www.frontiersin.org 7caspase-1 within the myofibroblast NLRP3 inflammasome to
mediate its anti-fibrotic effects (Figures 5A, B). To further
consolidate these results, we measured the levels of mature
caspase and IL-1b activity in caspase-1 siRNA transfected
HDMFs treated with T+L+A and also separately with T+L+A
+R (Figure 5C). In the presence of siRNA targeting caspase-1,
the ability of RLX to downregulate caspase-1 and IL-1b activity
was suppressed. These findings confirmed that RLX could
modulate the myofibroblast NLRP3 inflammasome at the levelA
B
FIGURE 2 | The effects of RLX on NLRP3 inflammasome priming and activity, and measures of fibrosis in T- and T+L+A-stimulated WT BJ3 HDMFs after 72 h.
(A) Representative Western blots of NLRP3, ASC, pro-caspase-1, pro-IL-1b and pro-IL-18, a-SMA (used as a marker of myofibroblast differentiation), and collagen I
protein expression from HDMFs stimulated with TGF-b1 (T; 5 ng/ml), T+R (RLX; 100 ng/ml), T+L(LPS; 100 ng/ml)+A(ATP; 5 mM), or T+L+A+R over 72 h. (B) Also
shown are the mean ± SEM of each end-point measured from each treatment group studied, corrected for GAPDH loading and expressed relative to the value in the
T-treated group, which was expressed as 1 in each case; from n=6–8 separate experiments conducted in duplicate. *p<0.05, **p<0.01 vs. T-alone treated group;
#p<0.05, ##p<0.01 vs. T+L+A-treated group. Immunofluoresence (red) staining of a-SMA in stress fibres (indicated by white arrows) in T+L+A-stimulated HDMFs
confirmed that these stimulated cells were myofibroblasts after 72 h of culture. 4′,6-diamidino-2-phenylindole (DAPI; blue) staining was used to detect cell nuclei.
Scale bar; 100 mm.August 2020 | Volume 11 | Article 1201
Pinar et al. Relaxin Directly Targets the NLRP3 Inflammasomeof caspase-1 to inhibit pro-IL-1b, pro-IL-18, myofibroblast
differentiation, and myofibroblast-induced collagen I deposition.DISCUSSION
RLX has emerged as a rapidly-acting anti-fibrotic therapy, and
at least at the experimental level, as a more efficacious anti-
fibrotic compared to the ACE inhibitor, enalapril (Samuel et al.,Frontiers in Pharmacology | www.frontiersin.org 82014). It was previously shown that RLX mediated its anti-
fibrotic effects through direct (Kocan et al., 2017) or indirect
(Mookerjee et al., 2009; Wang et al., 2016) activation of cGMP,
the latter involving nNOS-NO-sGC-cGMP signaling, to inhibit
TGF-b1 signal transduction at the level of intracellular Smad2
(Mookerjee et al., 2009; Samuel et al., 2014; Wang et al., 2016;
Kocan et al., 2017) and/or Smad3 (Kocan et al., 2017) in
myofibroblasts. This consistently resulted in the RLX-induced
inhibition of the pro-fibrotic influence of TGF-b1 onA
B
C
FIGURE 3 | The effects of RLX on Lipofectamine-induced CTL siRNA transfection in NLRP3 inflammasome activated BJ3 HDMFs after 72 h. (A) Representative
Western blots of NLRP3, ASC, pro-caspase-1, pro-IL-1b, pro-IL-18, a-SMA, and collagen-I protein expression in HDMFs treated with CTL siRNA ± T+L+A ± R
treatment after 72 h. (B) Also shown are the mean ± SEM of each end-point measured from each treatment group studied, corrected for GAPDH loading and
expressed relative to the value in the CTL siRNA+T+L+A-treated HDMF group, which was expressed as 1 in each case; from n=4–6 separate experiments
conducted in duplicate. #p<0.05 ##p<0.01 vs. CTL siRNA+T+L+A-treated group. (C) Additionally shown are the mean ± SEM levels of active caspase-1 (pg/ml) (top
panel) and active IL-1b (pg/ml) (bottom panel) in CTL siRNA transfected HDFs treated with T+L+A or T+L+A+R after 72 h.August 2020 | Volume 11 | Article 1201
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collagen deposition, in the absence of RLX having any direct
effects on collagen (Unemori et al., 1996; Samuel et al., 2004).
Given that the inflammatory cytokine, IL-1b, can promote
fibrosis progression through an autocrine loop with the TGF-
b1/Smad3 axis (Bonniaud et al., 2005; Aoki et al., 2006), and
that RLX was found to inhibit collagen synthesis from either IL-
1b or TGF-b1-stimulated HDMFs (Unemori and Amento,
1990), our recent attention turned to how RLX disrupted the
TGF-b1/IL-1b interaction. As RLX was also found to inhibit
renal fibrosis through a TLR-4-dependent mechanism (Chen
et al., 2017), which is a known inducer of the myofibroblast
NLRP3 inflammasome (Boza et al., 2016), and IL-1b along withFrontiers in Pharmacology | www.frontiersin.org 9IL-18 can be produced by this inflammasome (Artlett and
Thacker, 2015), we investigated whether RLX targeted TGF-
b1 and TLR-4-induced NLRP3 inflammasome activity in
myofibroblasts to mediate its anti-fibrotic actions.
Our recent findings revealed that RLX signaled through a
RXFP1-nNOS-TLR-4-dependent mechanism in human cardiac
myofibroblasts in vitro and in a murine model of isoproterenol-
induced cardiomyopathy in vivo to inhibit measures of
myofibroblast NLRP3 inflammasome priming and activity, as
well as myofibroblast differentiation and collagen I deposition
(Cáceres et al., 2019). These findings extended the above-
mentioned studies in demonstrating that RLX could ameliorate
NLRP3 inflammasome activity in myofibroblasts to inhibit theA
B
FIGURE 4 | Lipofectamine-mediated siRNA-induced knock-down of NLRP3, ASC or pro-caspase-1 after 8 or 72 h in BJ3 HDMFs. (A) Representative Western
blots of NLRP3, ASC and pro-caspase-1 protein expression in HDMFs treated with CTL siRNA+T, CTL siRNA+T+L+A, or NLRP3 siRNA+T+L+A, ASC siRNA+T+L
+A, or caspase-1 siRNA+T+L+A, respectively, after 8 or 72 h (where siRNA were added for only 24 h for the 72 h end-points measured). (B) Also shown are the
mean ± SEM of the transfection efficiency of each siRNA used against its target protein, at each time-point studied. Each measure was corrected for GAPDH loading
and expressed relative to the value in the CTL siRNA+T-treated group, which was expressed as 1 in each case; from n=4–6 separate experiments conducted in
duplicate. *p<0.05, **p<0.01 vs. CTL siRNA+T-treated group; #p<0.05, ##p<0.01 vs. CTL siRNA+T+L+A-treated group.August 2020 | Volume 11 | Article 1201
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(Figure 6) on myofibroblast differentiation and myofibroblast-
induced interstitial collagen deposition. Furthermore, they
somewhat confirmed previous reports which showed that RLX
could inhibit the pro-inflammatory and pro-fibrotic effects of IL-
1b and IL-18 in vivo, but which did not investigate NLRP3
inflammasome activity in the experimental models studied.
Despite these novel findings, it remained unclear as to whetherFrontiers in Pharmacology | www.frontiersin.org 10RLX modulated the myofibroblast NLRP3 inflammasome to
mediate its anti-fibrotic effects or was only able to indirectly
regulating the inflammasome at the level of the TGF-b1-TLR-4
axis on cardiac myofibroblasts (Boza et al., 2016). The findings
from this study, now show for the first time, that RLX can directly
modulate the myofibroblast NLRP3 inflammasome at the level of
caspase-1 to mediate its anti-fibrotic actions, as the ability of RLX
to inhibit pro-IL-1b, pro-IL-18, myofibroblast differentiation andA
B
C
FIGURE 5 | The effects of RLX in siRNA-transfected and NLRP3 inflammasome activated BJ3 HDMFs after 72 h. (A) Representative Western blots of NLRP3, ASC,
pro-caspase-1, pro-IL-1b, pro-IL-18, a-SMA, and collagen I protein expression in HDMFs transfected with CTL siRNA for 24 h and subsequently stimulated with T
+L+A ± R for 72 h; or NLRP3 siRNA, ASC siRNA, or caspase-1 siRNA for 24 h and subsequently stimulated with T+L+A+R for 72 h. (B) Also shown are the mean ±
SEM of protein expression levels of each end-point measured, corrected for GAPDH loading and expressed relative to the value in the CTL siRNA+T+L+A-treated
group; which was expressed as 1 in each case; from n=4–6 separate experiments conducted in duplicate. *p<0.05, **p<0.01 vs. the CTL siRNA+T+L+A-treated
group. (C) Additionally shown are the relative mean ± SEM levels of active caspase-1 (pg/ml) (top panel) and active IL-1b (pg/ml) (bottom panel) in caspase-1 siRNA
transfected HDFs treated with T+L+A or T+L+A+R after 72 h.August 2020 | Volume 11 | Article 1201
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knock-down of caspase-1, but not of NLRP3 or ASC. Collectively,
our findings suggest firstly that RLX (acting through RXFP1) can
target the TGF-b1-TLR-4 axis (upstream of the NLRP3
inflammasome) to inhibit NLRP3 and ASC; and secondly,
through disruption of the TGF-b1-TLR-4 axis and pro-caspase 1
(within the inflammasome), RLX can down-regulate caspase-1
activity to dampen the pro-fibrotic contributions of IL-1b and IL-
18, that is produced by the myofibroblast NLRP3 inflammasome,
on myofibroblast differentiation and collagen-I deposition
(Figure 6). Our added findings that RLX could disrupt TGF-b1-Frontiers in Pharmacology | www.frontiersin.org 11inducedmyofibroblast differentiation and collagen-I deposition, in
the absence of L+A-induced NLRP3 inflammasome activity,
additionally suggests that RLX does not exclusively regulate the
myofibroblast NLRP3 inflammasome to mediate its anti-fibrotic
actions. Consistent with this, studies have shown that RLX can
also suppress the upregulation of several chemokines and
cytokines independently of IL-1b and/or IL-18 regulation
(reviewed in Bathgate et al., 2013; Samuel et al., 2017). Our
findings show that RLX is able to disrupt the TGF-b1-IL-1b and
TGF-b1-IL-18 axes through the NLRP3 inflammasome
on myofibroblasts.FIGURE 6 | Progressive studies that we and others have published, have led to our recent findings showing that RLX signaled through a RXFP1-nNOS-TLR-4-
dependent mechanism in human cardiac myofibroblasts to inhibit measures of myofibroblast NLRP3 inflammasome priming and activity, as well as myofibroblast
differentiation and myofibroblast-induced collagen I deposition (Cáceres et al., 2019). We now show in this study that RLX can additionally modulate the
myofibroblast NLRP3 inflammasome at the level of caspase-1 to mediate its anti-fibrotic actions; as the ability of RLX to inhibit IL-1b, pro-IL-18, myofibroblast
differentiation and collagen I deposition was specifically abrogated by siRNA-induced knock-down of caspase-1, but not of NLRP3 or ASC. Our collective findings
suggest that RLX can target the TGF-b1-TLR-4 axis (upstream of the NLRP3 inflammasome) to inhibit NLRP3, ASC and pro-caspase-1; and also target caspase-1
activity (within the NLRP3 inflammasome) to inhibit the pro-fibrotic contributions of IL-1b and IL-18 that is produced by the NLRP3 inflammasome, on myofibroblast
differentiation (a-SMA expression) and collagen I deposition.August 2020 | Volume 11 | Article 1201
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suggest that pro-caspase-1 and caspase-1 activity can be
regulated independently of NLRP3 and/or ASC. As T-alone
(without L+A) was found to stimulate pro-caspase-1 protein
expression after 72 h (Supplementary Table 1), in the absence of
NLRP3 or ASC in HDMFs, this provides evidence to suggest that
pro-caspase-1 can be regulated independently of NLRP3 and
ASC, and independently of NLRP3 inflammasome induction.
This notion is in line with previous studies which demonstrated
that caspase-1 activity can be regulated upstream of the NLRP3
inflammasome, at the level of TLR-4 and NF-kB activation
(Kahlenberg et al., 2005; Franchi et al., 2009). On the other
hand, as T+L+A stimulation promoted NLRP3-dependent
caspase-1 and IL-1b activity in HDMFs, this confirmed the
NLRP3-dependent induction of caspase-1 and IL-1b activity,
consistent with previous studies (Martinon et al., 2002;
Sutterwala et al., 2006; Bauernfeind et al., 2009; Cáceres et al.,
2019). Therefore, it is possible that caspase-1 can be regulated via
NLRP3-dependent and -independent mechanisms. Hence,
further work is required to determine how RLX specifically
targets caspase-1 activity on myofibroblasts.
Nevertheless, our findings overlap but are distinct from a
previous study, which demonstrated that RLX could attenuate
caspase-1 activity in an in vivo model of ischemia/reperfusion
injury via an eNOS-dependent mechanism (Valle Raleigh et al.,
2017), in which the direct involvement of the NLRP3
inflammasome was not provided (Valle Raleigh et al., 2017). As
NO has been found to inhibit caspase-1, IL-1b, and IL-18 release
from macrophages (Collino et al., 2013), it was suggested that the
ability of RLX to promote eNOS-induced NO correlated with the
RLX-induced attenuation of NLRP3 inflammasome-induced
caspase-1 that was measured in the murine model studied (Valle
Raleigh et al., 2017). However, several lines of evidence have
indicated RLX to signal via a nNOS-dependent mechanism in
myofibroblasts. Rat renal myofibroblasts (Mookerjee et al., 2009;
Chow et al., 2012) and human cardiac myofibroblasts (Sarwar et al.,
2015) express nNOS and iNOS but lack eNOS, with RLX shown to
specifically up-regulate nNOS expression in these myofibroblasts
(Mookerjee et al., 2009; Chow et al., 2012; Sarwar et al., 2015).
Furthermore, pharmacological blockade of nNOS activity in rat
renal myofibroblasts has been shown to inhibit the anti-fibrotic
effects of RLX on TGF-b1 signal transduction and myofibroblast
differentiation (Mookerjee et al., 2009). Therefore, it would appear
that RLX signals through a nNOS-dependent mechanism in
myofibroblasts to inhibit TLR-4-NLRP3 inflammasome-caspase-
1-IL-1b/IL-18 activity. On the other hand, RLX may regulate the
NLRP3 inflammasome in other cells such as macrophages through
an eNOS-NO- (Sogawa et al., 2018) or iNOS-NO- (Mao et al.,
2013) dependent mechanism. Irrespective of how NO is produced
by various cells, both our findings and those of Valle Raleigh (Valle
Raleigh et al., 2017) and colleagues suggest that the RLX-induced
promotion of NO can target caspase-1 release and activity within
the NLRP3 inflammasome in multiple cell types, and its subsequent
ability to activate IL-1b and IL-18.
The expression and activity of the NLRP3 inflammasome from
different cell types (including various innate immune cells andFrontiers in Pharmacology | www.frontiersin.org 12myofibroblasts) is likely to be varied during wound healing-
induced inflammation, tissue remodeling and eventually
fibrogenesis (Yin et al., 2009). During the inflammatory phase of
the wound healing response, the macrophage NLRP3
inflammasome is highly expressed and plays a fundamental role
in secreting IL-1b and IL-18, which along with the TGF-b1 that is
secreted by macrophages, contribute to the activation of resident
ECM-producing fibroblasts (Wynn and Barron, 2010). Although
not expressed as highly as their macrophage counterparts,
myofibroblast NLRP3 inflammasome components, such as
NLRP3 and ASC, have been detected during the early stages of
wound healing in response to injury (Mezzaroma et al., 2011; Gan
et al., 2018). However, the IL-1b that is secreted by themyofibroblast
NLRP3 inflammasome has been demonstrated to promote the
effects of TGF-b1 on human fibroblast proliferation and ECM
synthesis, eventually contributing to adverse tissue remodeling
and fibrosis (Vesey et al., 2002). Similarly, the epithelial cell
NLRP3 inflammasome has been found to contribute to epithelial-
mesenchymal-transition (EMT) during wound healing-associated
inflammation in response to tissue injury, which over time,
contributes to fibrogenesis via an interaction with TGF-b1 (Liu,
2004; Wang et al., 2013). Hence, further work is required to
determine whether RLX universally targets NLRP3 inflammasome
activity, and indeed the activity of other inflammasomes that
contribute to fibrosis progression, or has temporal effects in
suppressing over-activated inflammasome activity in a cell-
dependent manner, to mediate its anti-fibrotic effects.
The findings from this study have provided further insight
into the molecular mechanisms by which RLX mediates its anti-
fibrotic actions on TGF-b1 signal transduction and its
interaction with the myofibroblast NLRP3 inflammasome. It is
now clear that RLX can act at multiple levels to disrupt the pro-
fibrotic influence of TGF-b1, through its ability to promote
nNOS-induced NO and cGMP in myofibroblasts. RLX can
disrupt TGF-b1 signal transduction at the level of Smad2 and/
or Smad3 (Heeg et al., 2005; Mookerjee et al., 2009; Sassoli et al.,
2013; Samuel et al., 2014; Wang et al., 2016; Kocan et al., 2017). It
can also ameliorate the interaction between TGF-b1 and TLR-4
(up-stream of the NLRP3 inflammasome) (Cáceres et al., 2019)
and caspase-1 activity (at the level of the NLRP3 inflammasome)
to suppress IL-1b and IL-18 activity, as well as the interaction
between TGF-b1 and secreted IL-1b (down-stream of the NLRP3
inflammasome) to mediate its anti-fibrotic actions (Figure 6). In
summary, these findings highlight the therapeutic relevance of
targeting the myofibroblast NLRP3 inflammasome as a means of
treating the fibrosis that is a key cause of tissue dysfunction and
failure. In this regard, natural (Molteni et al., 2018) and
pharmacological inhibitors (Matsunaga et al., 2011) of TLR-4,
NLRP3 (Coll et al., 2015), caspase-1 (Kudelova et al., 2015), or
IL-1b (Kudelova et al., 2015; Emmi et al., 2018) activity may limit
the contribution of the NLRP3 inflammasome to fibrosis
progression, while avoiding the redundancy and side-effects
associated with TGF-b1 blockade alone. However, future
studies aimed at combining these drugs with RLX may lead to
more efficacious blockade of fibrosis through suppression of the
TGF-b1-TLR-4-NLRP3 inflammasome axis.August 2020 | Volume 11 | Article 1201
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